# Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

> **NCT01632917** · PHASE1 · COMPLETED · sponsor: **Kythera Biopharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ATX-101 - U.S.
- **DRUG:** ATX-101 - EU

## Key facts

- **NCT ID:** NCT01632917
- **Lead sponsor:** Kythera Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632917, "Open-Label Pharmacokinetic Study of Final Formulations of ATX-101". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01632917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*